Common appliance raises kids' cancer risk nearly twice as much as adults' — and it's in 2 out of 5 US homes
Benzene, a harmful chemical found in gasoline, cigarette smoke and paint strippers, is a known carcinogen. Long-term exposure to high levels of benzene has been linked to leukemia and other blood-related cancers.
Now, a new study out of Stanford University reports that benzene-caused cancer risks are significantly higher — especially for children — in homes with medium to high usage of gas stoves and inadequate ventilation.
'Natural gas and propane stoves emit benzene, a known carcinogen through combustion,' the researchers explained in the forthcoming July issue of the Journal of Hazardous Materials.
'To our knowledge, ours is the first study to assess the carcinogenic health risks from benzene formed during gas combustion from stoves, as well as leukemia cases attributable to gas stove use.'
For the study, researchers simulated different cooking scenarios involving varying burner intensities and oven temperatures with minimal or no ventilation.
When there's no ventilation, benzene exposure in kitchens and living rooms is highest in smaller apartments, followed by manufactured homes, attached homes and detached homes, the researchers found.
'Particularly concerning were the elevated risks in bedrooms, where people typically spend the most time,' they wrote.
Their analysis also suggested that children's cancer risk from gas stove exposure is 1.85 times higher than adults.
The researchers noted that children generally breathe faster and take in more air — and therefore more pollutants — relative to their smaller body size.
'Since there is no safe limit for benzene's carcinogenic effects, it is crucial to further evaluate the health risks associated with these effects,' the study read.
Ventilation plays a key role in reducing benzene concentrations — the researchers recommend opening windows and using good-quality outdoor vent hoods. Homeowners could also switch to electric stoves.
'The study underscores the importance of addressing combustion-related indoor air pollutants to protect public health, particularly in households with limited ventilation,' the study authors wrote.
Gas stoves have come under fire in recent years as studies suggested they emit pollutants like nitrogen dioxide, carbon monoxide, benzene and formaldehyde, which can trigger asthma and potentially increase the risk of heart disease and other health problems.
The stoves have fueled heated debate about health and environmental concerns and government overreach with limitations or bans.
President Donald Trump signed an executive order in January that 'safeguards the American people's freedom to choose from a variety of goods and appliances,' including gas stoves.
The order followed a watered-down rule from the Biden administration requiring some gas and electric stoves to be more efficient.
Other restrictions have had more teeth. In 2023, New York became the first state to ban the installation of new gas stoves in most new homes and buildings. It's set to take effect in 2026 for buildings under seven stories and in 2029 for larger structures.
NYC also has a ban on natural gas in new buildings — the ordinance was upheld in federal court in March.
Meanwhile, research on the potential effects of gas stoves continues. About 38% of American households, or roughly 40 million homes, have these appliances.
Stanford scientists say that 6.3 million Americans are exposed to the top 5 % highest benzene-emitting gas stoves.
They measured emissions in 87 homes across 14 counties in Colorado and California for a 2023 study.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
2 hours ago
- Forbes
Novel Access Model For Sickle Cell Disease Gene Therapy Could Be Template
The Centers for Medicare and Medicaid Services announced in July that 33 states, the District of Columbia and Puerto Rico will join a new voluntary program intended to improve patient access to and lower costs for gene therapies targeting sickle cell disease. This was a Biden administration initiative, which the Trump administration decided to continue to implement. It ties payment for two novel gene therapies to positive clinical outcomes. This could make such treatments that cost millions be more widely accessible for patients. And if successful, it may serve as a template for future cell and gene therapy agreements. Medicaid, the joint federal and state program that provides health coverage to low-income individuals, is the main insurer for SCD patients. The Biden administration announced last year that the manufacturers of Lyfgenia and Casgevy had entered into agreements with CMS to participate in the Cell and Gene Therapy Access Model, which allows CMS to negotiate outcomes-based agreements on behalf of state Medicaid programs for cell and gene therapies, beginning with sickle cell disease treatments. Essentially this means that CMS will reimburse based on whether certain agreed-upon clinical thresholds are reached in patients. According to CMS, the participating states in the newly established access initiative represent about 84% of Medicaid beneficiaries with SCD. The program could contribute towards a sizable expansion of access to potentially transformative care in the form of two extraordinarily expensive gene therapies. The launch prices for Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel) were $2.2 million and $3.1 million, respectively. SCD is a group of congenital red blood cell disorders, named sickle cell for their crescent shape. The condition affects millions of people worldwide. In the United States, approximately 100,000 individuals are living with the disease, which predominantly impacts people of sub-Saharan African descent. The disease alters the structure of hemoglobin, the molecule in red blood cells that delivers oxygen to organs and tissue throughout the body. As a consequence, this causes severe pain, anemia, organ damage and infections. Individuals with the disease have a shorter life expectancy, by more than 20 years on average. The most common sickle cell disorder type is sickle cell anemia. Besides pain medications to relieve symptoms as well as antibiotics to treat infections, hydroxyurea—a bone marrow suppressive agent that decreases red blood cell production—can be used to reduce the frequency of painful episodes. It has been in use since the 1980s. The Food and Drug Administration has approved several new therapeutics in the past ten years, but none are as promising as Lyfgenia and Casgevy. These two novel therapies can decrease or potentially eliminate pain crises in patients. Gene therapies such as Lyfgenia and Casgevy are administered in an inpatient hospital setting but are considered covered outpatient drugs because they're directly reimbursed and subject to standard, federally mandated Medicaid rebates. Manufacturers of the two treatments must also provide states with supplemental rebates (post-hoc discounts off of the list price) reflecting model-negotiated terms. In turn, states are obligated to implement an agreed-upon access policy for patients. According to CMS, there is also optional federal support of up to $9.55 million per state available to help with implementation of the arrangements, outreach and data tracking. In the cell and gene therapy space, science has generally outpaced commercialization. Access to very costly treatments is a challenge. Whether in the public or commercial sector, payers must find novel ways of paying for cell and gene therapies while generating evidence with respect to their real-world effectiveness and safety. Questions insurers must find answers to include: What are the health outcomes for patients in real-world settings? Do treatments fulfill the promise of a one-time cure for certain serious illnesses or disorders? Are there particular safety concerns that appear in real-world settings? Are side effects manageable? Coordinating evidence gathering as well as contracts across state Medicaid agencies is likely to yield a more efficient process while improving access for a substantial majority of SCD sufferers nationwide. It's not just SCD gene therapies that confront a formidable set of barriers to access. All cell and gene therapy manufacturers face a challenging environment. The regulatory hurdles are enormous to begin with, but manufacturing challenges following approval are considerable, too. Furthermore, patient preparation, side effect and adverse event profiles can be intolerable. This can deter patients from signing up to initiate treatment. On top of all of this, payers concerned about the high per unit costs often impose coverage restrictions, as the Tufts Center for the Evaluation of Value and Risk in Health describes. Nonetheless, gene therapies in particular hold the promise of delivering groundbreaking improvements in health outcomes across multiple disease areas. Therefore, overcoming obstacles to optimal patient access is crucial. If successful, the SCD model being experimented with could serve as a blueprint for other cell and gene therapies that have faced considerable barriers with respect to patient access.


USA Today
8 hours ago
- USA Today
Saquon Barkley among NFL stars who will join President Trump's council on Sports Nutrition
Eagles running back Saquon Barkley will join Harrison Butker, Nick Bosa, Tony Romo, and Lawrence Taylor on President Trumps Council on Sports, Fitness, and Nutrition.' Saquon Barkley is a son, a fantastic father, the NFL's Offensive Player of the Year winner, and now a member of President Donald Trump's administration. In a move that will revive a standard from the Reagan, Clinton, and Bush era, Barkley will join Harrison Butker, Nick Bosa, Tony Romo, and Lawrence Taylor on President Trump's Council on Sports, Fitness, and Nutrition.' According to the Washington Post, President Trump on Thursday announced that the presidential fitness test, a hallmark of American physical education programs, will be making a comeback in public schools. The assessment was retired and replaced by a fitness program under the Obama administration. The presidential fitness test was initiated in the 1950s by a council established by President Dwight D. Eisenhower that was directed to improve the physical fitness of American youths, in response to fears they were falling behind their European counterparts when it came to athleticism. The project is an alternative way to get anti-obesity drugs to Medicare and Medicaid patients, after the administration said in April that neither program would cover GLP-1s for weight loss. In doing so, it scrapped a 2024 Biden administration proposal for the programs to start covering GLP-1s for patients with obesity. Several high-profile athletes — all of whom have existing ties to Trump — attended the ceremony and will serve on the President's Council on Sports, Fitness and Nutrition. The attendees included professional golfer Bryson DeChambeau, who will chair the council; controversial National Football League kicker Harrison Butker; World Wrestling Entertainment mainstay Paul 'Triple H' Levesque; golfer Annika Sorenstam; and football Hall of Famer Lawrence Taylor. The Eagles running back wasn't in attendance, but will be joined by golfers Jack Nicklaus, Nelly Korda, and Gary Player (who was also awarded the Medal of Freedom alongside Sorenstam); Tony Romo, Nick Bosa, and Barkley; legendary hockey player Wayne Gretzky; and baseball player Mariano Rivera. The list also includes NFL Commissioner Roger Goodell, whom Trump repeatedly scrutinized during his first presidential term. Barkley was criticized during the off-season for spending time with President Trump on a golf outing prior to the Eagles' ring celebration.


Indianapolis Star
8 hours ago
- Indianapolis Star
'Eclipse of the century': Lengthy 6-minute solar eclipse is coming Aug. 2, 2027
No, the world will not go dark this weekend. Rumors about a lengthy total solar eclipse may have been circulating online, but the so-called "eclipse of the century" isn't for another two years. A total solar eclipse lasting up to 6 minutes and 23 seconds, at its peak, is expected to occur on Aug. 2, 2027, according to NASA. The total solar eclipse, in which the moon moves perfectly between the sun and Earth and casts a shadow on Earth, will be one of the longest in several decades. For a time comparison, the total solar eclipse that occured on April 8, 2024, lasted 4 minutes and 28 seconds at its peak. The solar eclipse of 1991, however, lasted 6 minutes and 53 seconds. reports the Aug. 2, 2027 eclipse will be the longest eclipse totality until 2114. The eclipse will be visible in parts of Africa, Europe and the Middle East. Unfortunately for American skywatchers, the vast majority of the U.S. won't have a view of it. The Aug. 2, 2027 solar eclipse isn't actually the next total solar eclipse though. That one, on Aug. 12, 2026, will be visible in Greenland, Iceland, Spain, Russia and parts of Portugal, according to NASA. Here's what to know about the solar eclipse on Aug. 2, 2027. The solar eclipse's path of totality will cross over parts of Africa, Europe and the Middle East, according to National Eclipse and NASA. Parts of the following countries are within the path of totality. Other countries in Africa, Europe and the Middle East will have a partial view of the eclipse. A partial solar eclipse will be visible in parts of Maine between 5:14 and 5:19 a.m. ET on Aug. 2, 2027, according to Time and Date.